Herpes simplex
☆ Na nsonaazụ Stiftung Warentest nke 2022 sitere na Germany, afọ ojuju ndị ahịa na ModelDerm dị ntakịrị ntakịrị karịa na nyocha telemedicine akwụ ụgwọ.
Herpes simplex na egbugbere ọnụ.
Herpes simplex ― Ọrịa Herpes simplex na mkpịsị aka na-adịkarị na ụmụaka karịa ndị okenye.
References
Ọrịa HSV-1 na-aga n'ihu site na ọrịa mbụ nke mkpụrụ ndụ epithelial, na-esote nkwụsịtụ, tumadi na neurons, na ịmaliteghachi. HSV-1 na-ebutekarị mgbawa vesicular nke mbụ na ugboro ugboro, ọkachasị n'ọnụ na mucosa genital. Ngosipụta ya sitere na herpes orolabial ruo ọnọdụ dị iche iche dị ka herpetic folliculitis, ọrịa anụ ahụ, itinye aka na anya, na ikpe siri ike dị ka herpes encephalitis. Ọgwụ nje na-enyere aka ijikwa ọrịa HSV.
Herpes simplex virus type 1 (HSV-1) is a member of the Alphaherpesviridae subfamily. Its structure is composed of linear dsDNA, an icosahedral capsid that is 100 to 110 nm in diameter, with a spikey envelope. In general, the pathogenesis of HSV-1 infection follows a cycle of primary infection of epithelial cells, latency primarily in neurons, and reactivation. HSV-1 is responsible for establishing primary and recurrent vesicular eruptions, primarily in the orolabial and genital mucosa. HSV-1 infection has a wide variety of presentations, including orolabial herpes, herpetic sycosis (HSV folliculitis), herpes gladiatorum, herpetic whitlow, ocular HSV infection, herpes encephalitis, Kaposi varicelliform eruption (eczema herpeticum), and severe or chronic HSV infection. Antiviral therapy limits the course of HSV infection.
Herpes simplex virus type 1 (HSV-1) is a member of the Alphaherpesviridae subfamily. Its structure is composed of linear dsDNA, an icosahedral capsid that is 100 to 110 nm in diameter, with a spikey envelope. In general, the pathogenesis of HSV-1 infection follows a cycle of primary infection of epithelial cells, latency primarily in neurons, and reactivation. HSV-1 is responsible for establishing primary and recurrent vesicular eruptions, primarily in the orolabial and genital mucosa. HSV-1 infection has a wide variety of presentations, including orolabial herpes, herpetic sycosis (HSV folliculitis), herpes gladiatorum, herpetic whitlow, ocular HSV infection, herpes encephalitis, Kaposi varicelliform eruption (eczema herpeticum), and severe or chronic HSV infection. Antiviral therapy limits the course of HSV infection.
Herpes simplex virus type 2 (HSV-2) bụ ọrịa na-efe efe zuru ebe niile, na-emetụta ihe dịka 22% nke ndị okenye gbara afọ 12 na karịa, na-agbakọta ndị okenye nde 45 na United States. Ọ bụ ezie na HSV-1 na-ebutekarị ọnya ọnụ, ọ nwekwara ike ibute ọnya anụ ahụ. Otú ọ dị, mgbe ndị ọrịa nwere ọnya genital, HSV-2 na-abụkarị nchegbu bụ isi. Mgbaàmà nke ntiwapụ nke HSV-2 na-adịkarị ụkọ, dị ka itching na mgbakasị ahụ, nke nwere ike igbu oge nyocha na ọgwụgwọ. Oge igbu oge a nwere ike bute mbufe ọzọ nye ndị na-enweghị ọrịa.
Herpes simplex virus type 2 (HSV-2) continues to be a common infection, affecting approximately 22% of adults ages 12 and older, representing 45 million adults in the United States alone. While HSV-1 often affects the perioral region and can be known to cause genital lesions, HSV-2 is more commonly the consideration when patients present with genital lesions. Despite this, most outbreaks of the infection will present with nonspecific symptoms such as genital itching, irritation, and excoriations, which may cause diagnosis and treatment to be delayed. As a result, further exposure to uninfected individuals may occur.
Herpes simplex virus type 2 (HSV-2) continues to be a common infection, affecting approximately 22% of adults ages 12 and older, representing 45 million adults in the United States alone. While HSV-1 often affects the perioral region and can be known to cause genital lesions, HSV-2 is more commonly the consideration when patients present with genital lesions. Despite this, most outbreaks of the infection will present with nonspecific symptoms such as genital itching, irritation, and excoriations, which may cause diagnosis and treatment to be delayed. As a result, further exposure to uninfected individuals may occur.
Herpes simplex virus (HSV) na-ebutekarị ọrịa dị ka genital herpes na oyi oyi na ndị nọ n'afọ iri na ụma na ndị okenye. Mgbe HSV na-ebute nwa ọhụrụ n'ime izu 4-6 mbụ nke ndụ, ọ nwere ike ibute ọrịa siri ike nke nwere nnukwu nsonaazụ. Ịchọpụta ngwa ngwa ọrịa HSV ọhụrụ dị mkpa iji kwụsị ọrịa ahụ ka ọ na-akawanye njọ, na-egbochi nsogbu akwara ozi (ọbụlagodi ọnwụ) .
Herpes simplex virus (HSV), a member of the Herpesviridae family, is a well-known cause of infections including genital herpes and herpes labialis in the adolescent and adult population. Transmission of HSV infection to an infant during the first 4-6 weeks of life can lead to devastating disease with the potential for poor outcomes. Early diagnosis is imperative when evaluating neonatal HSV infection in order to prevent further disease progression, neurological complications, and even death.
Herpes simplex virus (HSV), a member of the Herpesviridae family, is a well-known cause of infections including genital herpes and herpes labialis in the adolescent and adult population. Transmission of HSV infection to an infant during the first 4-6 weeks of life can lead to devastating disease with the potential for poor outcomes. Early diagnosis is imperative when evaluating neonatal HSV infection in order to prevent further disease progression, neurological complications, and even death.
Herpes simplex ọrịa na-efe efe nke ukwuu ma nwee ike ibunye ụmụ nwanyị dị ime na ụmụ ọhụrụ ha. Nje virus a nwere ike ịkpata nnukwu nsogbu ahụike ma ọ bụ ọbụna ọnwụ n'ime ụmụ amụrụ ọhụrụ. Ọ bụ ezie na ọ dị ụkọ n'oge ime n'onwe ya, ọ na-emekarị mgbe a na-amụ nwa. Ihe ize ndụ kachasị njọ ma ọ bụrụ na nne na-ebute ọrịa n'ime oge ime ime. Otú ọ dị, enwere ike ibelata ihe ize ndụ a site na iji ọgwụ mgbochi ma ọ bụ ịhọrọ ngalaba C n'ọnọdụ ụfọdụ.
Infection with herpes simplex is one of the most common sexually transmitted infections. Because the infection is common in women of reproductive age it can be contracted and transmitted to the fetus during pregnancy and the newborn. Herpes simplex virus is an important cause of neonatal infection, which can lead to death or long-term disabilities. Rarely in the uterus, it occurs frequently during the transmission delivery. The greatest risk of transmission to the fetus and the newborn occurs in case of an initial maternal infection contracted in the second half of pregnancy. The risk of transmission of maternal-fetal-neonatal herpes simplex can be decreased by performing a treatment with antiviral drugs or resorting to a caesarean section in some specific cases.
Infection with herpes simplex is one of the most common sexually transmitted infections. Because the infection is common in women of reproductive age it can be contracted and transmitted to the fetus during pregnancy and the newborn. Herpes simplex virus is an important cause of neonatal infection, which can lead to death or long-term disabilities. Rarely in the uterus, it occurs frequently during the transmission delivery. The greatest risk of transmission to the fetus and the newborn occurs in case of an initial maternal infection contracted in the second half of pregnancy. The risk of transmission of maternal-fetal-neonatal herpes simplex can be decreased by performing a treatment with antiviral drugs or resorting to a caesarean section in some specific cases.
Ụdị Herpes simplex virus (HSV) 1 na 2 na-ebute ọtụtụ mmadụ gburugburu ụwa. Ọtụtụ mgbe, nje a na-anọ jụụ n'ime mkpụrụ ndụ irighiri mgbe ọ mesasịrị akpụkpọ ahụ, mana ọ nwere ike ịmalitegharị ma emechaa, na-ebute ọnya oyi. Mgbe ụfọdụ, ọ na-ebute nsogbu ndị siri ike dị ka ọrịa anya, mbufụt nke ụbụrụ, ma ọ bụ ọnọdụ dị ize ndụ n'ime ụmụ amụrụ ọhụrụ na ndị na-enweghị usoro nchebe. Ọ bụ ezie na ọgwụ ndị dị ugbu a na-enyere aka ịchịkwa ọrịa na-efe efe, ihe ize ndụ nke iguzogide ọgwụ na mmetụta ndị dị na ya ka bụ nchegbu. Anyị chọrọ ọgwụ ọhụrụ iji lekwasị nje anya nke ọma.
Infection with herpes simplex virus (HSV) types 1 and 2 is ubiquitous in the human population. Most commonly, virus replication is limited to the epithelia and establishes latency in enervating sensory neurons, reactivating periodically to produce localized recurrent lesions. However, these viruses can also cause severe disease such as recurrent keratitis leading potentially to blindness, as well as encephalitis, and systemic disease in neonates and immunocompromised patients. Although antiviral therapy has allowed continual and substantial improvement in the management of both primary and recurrent infections, resistance to currently available drugs and long-term toxicity pose a current and future threat that should be addressed through the development of new antiviral compounds directed against new targets.
Infection with herpes simplex virus (HSV) types 1 and 2 is ubiquitous in the human population. Most commonly, virus replication is limited to the epithelia and establishes latency in enervating sensory neurons, reactivating periodically to produce localized recurrent lesions. However, these viruses can also cause severe disease such as recurrent keratitis leading potentially to blindness, as well as encephalitis, and systemic disease in neonates and immunocompromised patients. Although antiviral therapy has allowed continual and substantial improvement in the management of both primary and recurrent infections, resistance to currently available drugs and long-term toxicity pose a current and future threat that should be addressed through the development of new antiviral compounds directed against new targets.
Enwere ụdị abụọ nke nje herpes simplex , ụdị 1 (HSV-1) na ụdị 2 (HSV-2). HSV-1 na-ebutekarị ọrịa n'akụkụ ọnụ ebe HSV-2 na-ebutekarị ọrịa genital. A na-ebunye ha site na ịkpọtụrụ onye bu ọrịa ahụ ozugbo. A na-ekewa herpes genital dị ka ọrịa a na-ebute site ná mmekọahụ. Enwere ike ịgbasa ya na nwa ọhụrụ mgbe ọ na-amụ nwa. Mgbe ọrịa ahụ gasịrị, a na-ebufe nje ndị ahụ site na irighiri akwara na-ebuga n'ahụ cell irighiri, ebe ha na-ebi ogologo ndụ. Ihe kpatara nlọghachi azụ nwere ike ịgụnye: mbelata ọrụ mgbochi ọrịa, nchekasị, na ikpughe ìhè anyanwụ.
N'ọtụtụ ọnọdụ, a na-aṅụ ọgwụ mgbochi nje naanị mgbe mgbaàmà siri ike. Enwere ike ịnye onye na-ebutekarị ọrịa ọgwụ mgbochi kwa ụbọchị. Enweghị ọgwụ mgbochi ọ bụla dị na ọgwụ mgbochi shingles anaghị egbochi herpes simplex. Ọgwụgwọ na ọgwụ mgbochi nje dị ka aciclovir ma ọ bụ valaciclovir nwere ike ibelata ogo mgbaàmà.
Ọnụego mba ụwa nke HSV-1 ma ọ bụ HSV-2 dị n'etiti 60% na 95% na ndị okenye. HSV-1 na-ebutekarị ọrịa n'oge nwata. Ihe dị ka nde mmadụ 536 n'ụwa nile (16% nke ndị bi na ya) bu ọrịa HSV-2 dịka nke 2003 nwere ọnụ ọgụgụ dị ukwuu n'etiti ụmụ nwanyị na ndị nọ na mba ndị na-emepe emepe. Ọtụtụ ndị nwere HSV-2 anaghị aghọta na ha bu ọrịa.
○ Ọgwụgwọ ― OTC Ọgwụ
Zere mmetụ anụ ahụ ọ bụla, dị ka isutu nwatakịrị ọnụ, mgbe ọnya dị, n'ihi na kọntaktị nwere ike gbasaa ọrịa ahụ na ndị ọzọ. Ị kwesịrị izu ike na-aṅụghị mmanya.
#Acyclovir cream